Weigel H M, de Vries E, Regez R M, Henrichs J H, Ten Velden J J, Frissen P H, van der Meer J T
Department of Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
Scand J Infect Dis. 1997;29(5):499-502. doi: 10.3109/00365549709011862.
In a case-control study, prophylaxis with cotrimoxazole for toxoplasmic encephalitis (TE) in HIV-infected patients was evaluated. Cotrimoxazole had been given as PCP prophylaxis. 20 patients with TE were identified and 72 matching control cases were found. All patients had IgG-antibodies to Toxoplasma gondii and CD4+ T-cell counts < or = 100/microliter. The use and duration of cotrimoxazole prophylaxis were recorded. It was found that among the patients with TE, none had used cotrimoxazole for > 70% of the observation time, and that the 1-y incidence was 0% in the control group vs. 41% in those patients without sufficient cotrimoxazole use. The conclusion is that cotrimoxazole is effective as primary prophylaxis for TE, even in a dose of 480 mg daily.
在一项病例对照研究中，评估了复方新诺明对HIV感染患者弓形虫性脑炎（TE）的预防作用。复方新诺明此前一直用于预防肺孢子菌肺炎。确定了20例TE患者，并找到了72例匹配的对照病例。所有患者均有抗弓形虫IgG抗体，且CD4+T细胞计数≤100/微升。记录了复方新诺明预防用药的使用情况和持续时间。结果发现，在TE患者中，无人在超过70%的观察期内使用复方新诺明，对照组的1年发病率为0%，而未充分使用复方新诺明的患者中这一比例为41%。结论是，复方新诺明作为TE的一级预防有效，即使每日剂量为480毫克。
